QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
LON:SLN

Silence Therapeutics (SLN) Share Forecast, Price & News

GBX 535
-5.00 (-0.93%)
(As of 11/29/2021)
Compare
Today's Range
512
546
50-Day Range
535
535
52-Week Range
411
680
Volume
913,528 shs
Average Volume
80,100 shs
Market Capitalization
£480.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SLN stock logo

About Silence Therapeutics (LON:SLN) Stock

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Stock News Headlines

The Latest Analyst Ratings for Silence Therapeutics
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Silence Therapeutics PLC ADR
See More Headlines
Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Company Calendar

Last Earnings
9/14/2020
Today
5/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
74
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£11.35 million
Cash Flow
GBX 84.41 per share
Book Value
GBX 18.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£480.35 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Mark Andrew Rothera (Age 58)
    Pres, CEO & Exec. Director
    Comp: $521.23k
  • Dr. Giles V. Campion M.D. (Age 67)
    Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
    Comp: $436.2k
  • Mr. Craig A. Tooman M.B.A. (Age 55)
    MBA, Chief Financial Officer
  • Ms. Gem Gokmen Hopkins
    Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin (Age 61)
    Sr. VP, Gen. Counsel & Chief Patent Officer
  • Ms. Linnea Elrington
    VP & Head of HR
  • Dr. John Strafford
    VP & Head of Bus. Devel.
  • Mr. Jørgen Wittendorff
    Sr. VP & Head of Manufacturing
  • Dr. Marie Wikstrom Lindholm Ph.D.
    Sr. VP & Head of Molecular Design













SLN Stock - Frequently Asked Questions

How have SLN shares performed in 2023?

Silence Therapeutics' stock was trading at GBX 535 at the beginning of 2023. Since then, SLN shares have increased by 0.0% and is now trading at GBX 535.
View the best growth stocks for 2023 here
.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) announced its quarterly earnings results on Monday, September, 14th. The company reported ($13.70) EPS for the quarter, beating analysts' consensus estimates of ($21.70) by $8.00.

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How do I buy shares of Silence Therapeutics?

Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately GBX 535.

How much money does Silence Therapeutics make?

Silence Therapeutics (LON:SLN) has a market capitalization of £480.35 million and generates £11.35 million in revenue each year.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The official website for the company is www.silence-therapeutics.com. The company can be reached via phone at +44-20-34576900.

This page (LON:SLN) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -